Background

Lung cancer is the most frequently diagnosed cancer globally. In Malaysia, it ranks as the second most common cancer among men and third among women. Presently, no local clinical practice guidelines exist for lung cancer care in Malaysia. Given the lack of consensus regarding the perioperative management of early-stage non-small cell lung cancer (NSCLC), this article seeks to harmonise surgical practices among thoracic physicians and surgeons in Malaysia by recommending best practices for screening, diagnosis and staging, as well as multimodal management and surveillance in early-stage disease (stages I to IIIB-N2).

Methods

A local expert committee comprising nine high-volume actively practicing cardiothoracic or general thoracic surgeons gathered between February to July 2024 to deliberate existing evidence and formulate recommendations. A modified Delphi method comprising systematic review of published evidence and expert opinion based on local experience was utilised. The document was subsequently independently reviewed by two senior oncologists and two senior respiratory physicians, before incorporating their feedback into the final version.

Results

This document comprises a surgical consensus of evidence-based guidelines to provide local recommendations on contemporary real-world best practices. The consensus statements were grouped into five domains of early-stage resectable NSCLC: (I) screening (3 statements); (II) diagnosis and staging (6 statements); (III) neoadjuvant/perioperative immunotherapy (3 statements); (IV) adjuvant therapy with tyrosine kinase inhibitors (TKIs) or immunotherapy (4 statements); and (V) operative metrics and post-operative surveillance (5 statements).

Conclusions

These consensus statement guidelines will elevate and standardise the perioperative management of early-stage NSCLC in Malaysia, serve as a valuable educational and training tool for relevant medical professionals, and promote an inclusive, comprehensive multidisciplinary approach to integrated holistic patient care, aimed at improving both clinical outcomes and patients' quality of life with the best available evidence.

Keywords

Malaysia; Non-small cell lung cancer (NSCLC); perioperative; surgical consensus.

1. Aggarwal, C., Bubendorf, L., Cooper, W. A., & et al. (2021). Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges. Lung Cancer, 162, 42–53.
2. Albain, K. S., Swann, S. R., Rusch, V. W., & et al. (2009). Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. The Lancet, 374(9692), 379–386.
3. American Cancer Society. (2019). Cancer facts and figures 2019. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
4. Anand, K., Phung, T. L., Bernicker, E. H., & et al. (2020). Clinical utility of reflex ordered testing for molecular biomarkers in lung adenocarcinoma. Clinical Lung Cancer, 21(5), 437–442.
5. Andre, F., Grunenwald, D., Pujol, J. L., & et al. (2001). Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: Should prophylactic cranial irradiation be reconsidered? Cancer, 91(12), 2394–2400.
6. Araújo, A., Barroso, A., Parente, B., & et al. (2024). Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel. Pulmonology, 30(2), 159–169.
7. Asamura, H., Aokage, K., & Yotsukura, M. (2017). Wedge resection versus anatomic resection: Extent of surgical resection for stage I and II lung cancer. American Society of Clinical Oncology Educational Book, 37, 426–433.
8. Asmara, O. D., Hardavella, G., Ramella, S., & et al. (2024). Stage III NSCLC treatment options: Too many choices. Breathe, 20(2), Article 240047.
9. Barlesi, F., Gervais, R., Lena, H., & et al. (2011). Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: A multicenter phase II trial (GFPC 07-01). Annals of Oncology, 22(11), 2466–2470.
10. Bauman, K., & Arenberg, D. (2010). Multidisciplinary evaluation of patients with suspected lung cancer. Clinical Pulmonary Medicine, 17(1), 35–41.
11. Bhatt, S. P., Kim, Y. I., Harrington, K. F., & et al. (2018). Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax, 73(5), 414–421.
12. Bichakjian, C. K. (2015). Multidisciplinary care: For the sake of our patients. Journal of the National Comprehensive Cancer Network, 13(11), 1299–1300.
13. Blasberg, J. D., Pass, H. I., & Donington, J. S. (2010). Sublobar resection: A movement from the Lung Cancer Study Group. Journal of Thoracic Oncology, 5(10), 1583–1593.
14. Bott, M. J., Patel, A. P., Crabtree, D. T., & et al. (2015). Pathologic upstaging in patients undergoing resection for stage I non-small cell lung cancer: Are there modifiable predictors? The Annals of Thoracic Surgery, 100(6), 2048–2053.
15. Bousema, J. E., van Dorp, M., Hoeijmakers, F., & et al. (2019). Guideline adherence of mediastinal staging of non-small cell lung cancer: A multicentre retrospective analysis. Lung Cancer, 134, 52–58.
16. Bousema, J. E., van Dorp, M., Noyez, V. J. J. M., & et al. (2019). Unforeseen N2 disease after negative endosonography findings with or without confirmatory mediastinoscopy in resectable non-small cell lung cancer: A systematic review and meta-analysis. Journal of Thoracic Oncology, 14(9), 979–992.
17. Bray, F., Laversanne, M., Sung, H., & et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263.
18. British Thoracic Society Standards of Care Committee. (1998). BTS recommendations to respiratory physicians for organising the care of patients with lung cancer. Thorax, 53(Suppl 1), S1–S8.
19. Brunelli, A., Kim, A. W., Berger, K. I., & et al. (2013). Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e166S–e190S.
20. Calvo, V., Aliaga, C., Carracedo, C., & et al. (2021). Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review. Translational Lung Cancer Research, 10(1), 581–589.
21. Carolan, H., Sun, A. Y., Bezjak, A., & et al. (2005). Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer, 49(1), 109–115.
22. Cascone, T., Awad, M. M., Spicer, J. D., & et al. (2023). LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II-IIIb NSCLC. Annals of Oncology, 34(Suppl 2), S1295.
23. Cellina, M., Cacioppa, L. M., Cè, M., & et al. (2023). Artificial intelligence in lung cancer screening: The future is now. Cancers, 15(17), Article 4344.
24. Chang, G. C., Chiu, CH., Yu, C. J., & et al. (2024). Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: A prospective cohort study. The Lancet Respiratory Medicine, 12(2), 141–152.
25. Cheema, P. K., Menjak, I. B., Winterton-Perks, Z., & et al. (2017). Impact of reflex EGFR/ALK testing on time to treatment of patients with advanced nonsquamous non-small-cell lung cancer. Journal of Oncology Practice, 13(2), e130–e138.
26. Chen, D., & Yu, J. (2021). Effectiveness of postoperative or preoperative radiotherapy on prognosis in patients with stage II resectable non-small cell lung cancer: A retrospective study based on the SEER database. Medicina, 57(11), Article 1202.
27. Chen, M. F., & Chaft, J. E. (2023). Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: A narrative review. Translational Lung Cancer Research, 12(2), 337–345.
28. Chen, X., & Ma, K. (2021). Neoadjuvant therapy in lung cancer: What is most important: Objective response rate or major pathological response? Current Oncology, 28(5), 4129–4138.
29. Chevallier, M., Borgeaud, M., Addeo, A., & et al. (2021). Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. World Journal of Clinical Oncology, 12(4), 217–237.
30. Cushman, T. R., Jones, B., Akhavan, D., & et al. (2021). The effects of time to treatment initiation for patients with non-small-cell lung cancer in the United States. Clinical Lung Cancer, 22(4), e84–e97.
31. D'Amico, T. A. (2016). VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer. Journal of Thoracic Disease, 8(3), 296–297.
32. de Koning, H. J., van der Aalst, C. M., de Jong, P. A., & et al. (2020). Reduced lung-cancer mortality with volume CT screening in a randomized trial. New England Journal of Medicine, 382(6), 503–513.
33. de Margerie-Mellon, C., & Chassagnon, G. (2023). Artificial intelligence: A critical review of applications for lung nodule and lung cancer. Diagnostic and Interventional Imaging, 104(1), 11–17.
34. De Leyn, P., Dooms, C., Kuzdzal, J., & et al. (2014). Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery, 45(5), 787–798.
35. Deng, H., Liu, J., Cai, X., & et al. (2024). Upfront surgery for stage IIIA/B non-small cell lung cancer: Retrospective cohort study. BJS Open, 8(1), Article zrae008.
36. Detterbeck, F. C., Lewis, S. Z., Diekemper, R., & et al. (2013). Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), 7S–37S.
37. Divisi, D., De Vico, A., Zaccagna, G., & et al. (2020). Lobectomy versus sublobar resection in patients with non-small cell lung cancer: A systematic review. Journal of Thoracic Disease, 12(6), 3357–3362.
38. Doddoli, C., Thomas, P., Thirion, X., & et al. (2001). Postoperative complications in relation with induction therapy for lung cancer. European Journal of Cardio-Thoracic Surgery, 20(2), 385–390.
39. Doll, R., & Peto, R. (1978). Cigarette smoking and bronchial carcinoma: Dose and time relationships among regular smokers and lifelong non-smokers. Journal of Epidemiology and Community Health, 32(4), 303–313.
40. Dubin, S., & Griffin, D. (2020). Lung cancer in non-smokers. Missouri Medicine, 117(5), 375–379.
41. Edwards, D. M., Pirzadeh, M., Van, T., & et al. (2024). Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancer. Cancer, 130(16), 2910–2917.
42. Ettinger, D. S., Wood, D. E., Aisner, D. L., & et al. (2023). NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. Journal of the National Comprehensive Cancer Network, 21(4), 340–350.
43. Expert Consensus Panel. (2023). The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery, 166(3), 637–654.
44. Felip, E., Altorki, N., Zhou, C., & et al. (2021). Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. The Lancet, 398(10308), 1344–1357.
45. Felip, E., Altorki, N., Zhou, C., & et al. (2023). Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase III trial. Annals of Oncology, 34(10), 907–919.
46. Flanders, W. D., Lally, C. A., Zhu, B. P., & et al. (2003). Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: Results from Cancer Prevention Study II. Cancer Research, 63(20), 6556–6562.
47. Forde, M. P., Spicer, J., Lu, S., & et al. (2022). Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. New England Journal of Medicine, 386(21), 1973–1985.
48. Forde, M. P., Spicer, J. D., Provencio, M., & et al. (2025). Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. New England Journal of Medicine. Advance online publication.
49. Fowler, W. C., Langer, C. J., Curran, W. J., Jr., & et al. (1993). Postoperative complications after combined neoadjuvant treatment of lung cancer. The Annals of Thoracic Surgery, 55(4), 986–989.
50. Fujita, S., Katakami, N., Takahashi, Y., & et al. (2006). Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery, 29(6), 896–901.
51. Garzon, J. C., Ng, C. S., Sihoe, A. D., & et al. (2006). Video-assisted thoracic surgery pulmonary resection for lung cancer in patients with poor lung function. The Annals of Thoracic Surgery, 81(6), 1996–2003.
52. Gaspar, L. E., Chansky, K., Albain, K. S., & et al. (2005). Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: A retrospective review by the Southwest Oncology Group. Journal of Clinical Oncology, 23(13), 2955–2961.
53. Ginsberg, R. J., & Rubinstein, L. V. (1995). Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. The Annals of Thoracic Surgery, 60(3), 615–623.
54. Gómez-Caro, A., Garcia, S., Reguart, N., & et al. (2010). Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan. European Journal of Cardio-Thoracic Surgery, 37(5), 1168–1174.
55. Goss, G., Darling, G. E., Westeel, V., & et al. (2024). LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC). Annals of Oncology, 35(Suppl 2), S1238.
56. Grover, H., King, W., Bhattarai, N., & et al. (2022). Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography. Lung Cancer, 170, 20–33.
57. Grunnet, M., & Sorensen, J. B. (2012). Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer, 76(2), 138–143.
58. Harada, H., Okada, M., Sakamoto, T., & et al. (2005). Functional advantage after radical segmentectomy versus lobectomy for lung cancer. The Annals of Thoracic Surgery, 80(6), 2041–2045.
59. Heineman, D. J., Beck, N., Wouters, M. W., & et al. (2018). The Dutch national clinical audit for lung cancer: A tool to improve clinical practice? An analysis of unforeseen ipsilateral mediastinal lymph node involvement in the Dutch Lung Surgery Audit (DLSA). European Journal of Surgical Oncology, 44(6), 830–834.
60. Hendriks, L. E., Kerr, K. M., Menis, J., & et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(4), 339–357.
61. Heymach, J. V., Harpole, D., Mitsudomi, T., & et al. (2023). Perioperative durvalumab for resectable non-small-cell lung cancer. New England Journal of Medicine, 389(18), 1672–1684.
62. Howington, J. A., Blum, M. G., Chang, A. C., & et al. (2013). Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e278S–e313S.
63. Hudson, Z., Internullo E., Edey A., & et al. (2017). Brain imaging before primary lung cancer resection: A controversial topic. Ecancermedicalscience, 11, Article 749.
64. Hudson, B. J., Crawford, M. B., & Curtin, J. J. (2015). Brain imaging in lung cancer patients without symptoms of brain metastases: A national survey of current practice in England. Clinical Radiology, 70(6), 610–613.
65. IJsseldijk, M. A., Ten Broek, R. P. G., Wiering, B., & et al. (2021). Oncological outcomes of unsuspected pN2 in patients with non-small-cell lung cancer: A systematic review and meta-analysis. Interactive CardioVascular and Thoracic Surgery, 32(5), 727–36.
66. Jeong, Y., Lee, K. S., Shin, K. M., & et al. (2008). Efficacy of PET/CT in the characterization of solid or partly solid solitary pulmonary nodules. Lung Cancer, 61(2), 186–194.
67. Jiang, G., Yang, F., Li, X., & et al. (2011). Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer. World Journal of Surgical Oncology, 9, Article 170.
68. Kandathil, A., Kay, F. U., Butt, Y. M., & et al. (2018). Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. RadioGraphics, 38(7), 2134–2149.
69. Kaseda, K. (2020). Recent and current advances in FDG-PET imaging within the field of clinical oncology in NSCLC: A review of the literature. Diagnostics, 10(8), Article 561.
70. Kay, F. U., Kandathil, A., Batra, K., & et al. (2017). Revisions to the Tumor, Node, Metastasis staging of lung cancer (8th edition): Rationale, radiologic findings and clinical implications. World Journal of Radiology, 9(6), 269–279.
71. Henz Concatto, N., Watte, G., Marchiori, E., & et al. (2016). Magnetic resonance imaging of pulmonary nodules: Accuracy in a granulomatous disease-endemic region. European Radiology, 26(9), 2915–20.
72. Kirmani, B. H., Rintoul, R. C., Win, T., & et al. (2013). Stage migration: Results of lymph node dissection in the era of modern imaging and invasive staging for lung cancer. European Journal of Cardio-Thoracic Surgery, 43(1), 104–110.
73. Knapp, B. J., Devarakonda, S., & Govindan, R. (2022). Bone metastases in non-small cell lung cancer: A narrative review. Journal of Thoracic Disease, 14(5), 1696–1712.
74. Kong, F. M., Ten Haken, R., Eisbruch, A., & et al. (2005). Non-small cell lung cancer therapy-related pulmonary toxicity: An update on radiation pneumonitis and fibrosis. Seminars in Oncology, 32(Suppl 3), S42–S54.
75. Lam, D. C., Liam, C. K., Andarini, S., & et al. (2023). Lung cancer screening in Asia: An expert consensus report. Journal of Thoracic Oncology, 18(10), 1303–1322.
76. Lee, D. H., Kim, B., Keum, D. Y., & et al. (2013). Long term survival of patients with unsuspected N2 disease in non-small cell lung cancer. The Korean Journal of Thoracic and Cardiovascular Surgery, 46(1), 49–55.
77. Lee, J. M., Tsuboi, M., & Brunelli, A. (2022). Surgical perspective on neoadjuvant immunotherapy in non-small cell lung cancer. The Annals of Thoracic Surgery, 114(5), 1505–1515.
78. Levy, A., Faivre-Finn, C., Hasan, B., & et al. (2018). Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. European Journal of Cancer, 93, 37–46.
79. Liam, C. K., Pang, Y. K., Leow, C. H., & et al. (2006). Changes in the distribution of lung cancer cell types and patient demography in a developing multiracial Asian country: Experience of a university teaching hospital. Lung Cancer, 53(1), 23–30.
80. Lim, C., Tsao, M. S., Le, L. W., & et al. (2015). Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Annals of Oncology, 26(7), 1415–1421.
81. Lim, E., Baldwin, D., Beckles, M., & et al. (2010). Guidelines on the radical management of patients with lung cancer. Thorax, 65(Suppl 3), iii1–iii27.
82. Lim, E., Batchelor, T. J. P., Dunning, J., & et al. (2022). Video-assisted thoracoscopic or open lobectomy in early-stage lung cancer. NEJM Evidence, 1(3), Article EVIDoa2100016.
83. Lin, Y., Qureshi, M. M., Tapan, U., & et al. (2021). Reducing delays to lung cancer treatment through systematic consult scheduling: A multidisciplinary quality improvement initiative at a safety-net hospital. Journal of Clinical Oncology, 39(15_suppl), Article e18640.
84. Lindeman, N. I., Cagle, P. T., Aisner, D. L., & et al. (2018). Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Journal of Molecular Diagnostics, 20(2), 129–159.
85. LoPiccolo, J., Gusev, A., Christiani, D. C., & et al. (2024). Lung cancer in patients who have never smoked—an emerging disease. Nature Reviews Clinical Oncology, 21(2), 121–146.
86. Lordick, F., & Gockel, I. (2016). Chances, risks and limitations of neoadjuvant therapy in surgical oncology. Innovative Surgical Sciences, 1(1), 3–11.
87. Lu, S., Zhang, W., Wu, L., & et al. (2024). Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: The Neotorch randomized clinical trial. JAMA, 331(3), 201–211.
88. Malhotra, J., Malvezzi, M., Negri, E., & et al. (2016). Risk factors for lung cancer worldwide. European Respiratory Journal, 48(3), 889–902.
89. Martin, J., Ginsberg, R. J., Abolhoda, A., & et al. (2001). Morbidity and mortality after neoadjuvant therapy for lung cancer: The risks of right pneumonectomy. The Annals of Thoracic Surgery, 72(4), 1149–1154.
90. Ministry of Health Malaysia. (2015). National Health & Morbidity Survey 2015: Report on smoking status among Malaysian adults. https://www.moh.gov.my/moh/resources/NHMS2015-VolumeV.pdf
91. Ministry of Health Malaysia. (2018). Malaysian Study on Cancer Survival (MySCan) 2018. https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/Malaysian_Study_on_Cancer_Survival_MySCan_2018.pdf
92. Ministry of Health Malaysia. (2019). Malaysia National Cancer Registry Report 2012-2016. https://www2.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/2012-2016%20(MNCRR)/MNCR_2012-2016_FINAL_(PUBLISHED_2019).pdf
93. Ministry of Health Malaysia. (2024). Summary of Malaysia National Cancer Registry Report 2017-2021. https://nci.moh.gov.my/images/pdf_folder/SUMMARY-OF-MALAYSIA-NATIONAL-CANCER-REGISTRY-REPORT-2017-2021.pdf
94. Moro-Sibilot, D., Smit, E., de Castro Carpeño, J., & et al. (2015). Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer, 90(3), 427–432.
95. Myrdal, G., Lambe, M., Hillerdal, G., & et al. (2004). Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax, 59(1), 45–49.
96. Nasralla, A., Lee, J., Dang, J., & et al. (2020). Elevated preoperative CEA is associated with subclinical nodal involvement and worse survival in stage I non-small cell lung cancer: A systematic review and meta-analysis. Journal of Cardiothoracic Surgery, 15, Article 318.
97. National Lung Screening Trial Research Team. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 365(5), 395–409.
98. National Health Service (NHS). (2000). The NHS Cancer Plan 2000. https://image.guardian.co.uk/sys-files/Society/documents/2003/08/26/cancerplan.pdf
99. National Comprehensive Cancer Network (NCCN). (2025). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-small cell lung cancer version 7.2025. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
100. National Institute for Health and Care Excellence (NICE). (2019). Lung cancer: Diagnosis and management (NICE Guideline NG122). https://www.nice.org.uk/guidance/ng122
101. O'Brien, M., Paz-Ares, L., Marreaud, S., & et al. (2022). Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. The Lancet Oncology, 23(10), 1274–1286.
102. Passaro, A., Mok, T., Peters, S., & et al. (2021). Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. Journal of Thoracic Oncology, 16(5), 764–773.
103. Passlick, B., Born, C., Sienel, W., & et al. (2001). Incidence of chronic pain after minimal-invasive surgery for spontaneous pneumothorax. European Journal of Cardio-Thoracic Surgery, 19(3), 355–358.
104. Petersen, R. P., Pham, D., Burfeind, W. R., & et al. (2007). Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. The Annals of Thoracic Surgery, 83(4), 1245–1249.
105. Pless, M., Stupp, R., Ris, H. B., & et al. (2015). Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: A phase 3 randomised trial. The Lancet, 386(10000), 1049–1056.
106. Port, J. L., Mirza, F. M., Lee, P. C., & et al. (2011). Lobectomy in octogenarians with non-small cell lung cancer: Ramifications of increasing life expectancy and the benefits of minimally invasive surgery. The Annals of Thoracic Surgery, 92(6), 1951–1957.
107. Postmus, P. E., Kerr, K. M., Oudkerk, M., & et al. (2017). Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 28(Suppl 4), iv1–iv21.
108. Rajadurai, P., Cheah, P. L., How, S. H., & et al. (2019). Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society. Lung Cancer, 136, 65–73.
109. Rajadurai, P., How, S. H., Liam, C. K., & et al. (2020). Lung cancer in Malaysia. Journal of Thoracic Oncology, 15(3), 317–323.
110. Rami-Porta, R., Nishimura, K. K., Giroux, D. J., & et al. (2024). The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 19(7), 1007–1027.
111. Rangachari, D., Yamaguchi, N., VanderLaan, P. A., & et al. (2015). Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer, 88(1), 108–111.
112. Ridge, C. A., McErlean, A. M., & Ginsberg, M. S. (2013). Epidemiology of lung cancer. Seminars in Interventional Radiology, 30(2), 93–98.
113. Riely, G. J., Wood, D. E., Ettinger, D. S., & et al. (2024). Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(4), 249–274.
114. Sachithanandan, A., Lockman, H., Azman, R. R., & et al. (2024). The potential role of artificial intelligence-assisted chest X-ray imaging in detecting early-stage lung cancer in the community—a proposed algorithm for lung cancer screening in Malaysia. Medical Journal of Malaysia, 79(1), 9–14.
115. Sachithanandan, A., Sajak, A. A. B., & Hoh, H. H. (2024). Pre-operative carcino-embryonic antigen prognosticates early disease-free survival following curative surgery for non-small cell lung cancer. Medical Journal of Malaysia, 79(5), 683–689.
116. Saji, H., Okada, M., Tsuboi, M., & et al. (2022). Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. The Lancet, 399(10335), 1607–1617.
117. Saw, S. P. L., Zhong, W. Z., Fu, R., & et al. (2025). Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer. Lung Cancer, 200, Article 108076.
118. Schoenmaekers, J., Hofman, P., Bootsma, G., & et al. (2019). Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study. European Journal of Cancer, 115, 88–96.
119. Schreuder, A., Schaefer-Prokop, C. M., Scholten, E. T., & et al. (2018). Lung cancer risk to personalise annual and biennial follow-up computed tomography screening. Thorax, 73(7), 621–627.
120. Semik, M., Riesenbeck, D., Linder, A., & et al. (2004). Preoperative chemotherapy with and without additional radiochemotherapy: Benefit and risk for surgery of stage III non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery, 26(6), 1205–1210.
121. Shah, A. A., Berry, M. F., Tzao, C., & et al. (2012). Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. The Annals of Thoracic Surgery, 93(6), 1807–1812.
122. Shimada, Y., Saji, H., Yoshida, K., & et al. (2012). Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage IA non-small-cell lung cancer after complete surgical resection. Journal of Thoracic Oncology, 7(8), 1263–1270.
123. Shiraishi, T., Shirakusa, T., Iwasaki, A., & et al. (2004). Video-assisted thoracoscopic surgery (VATS) segmentectomy for small peripheral lung cancer tumors: Intermediate results. Surgical Endoscopy, 18(11), 1657–1662.
124. Sienel, W., Dango, S., Kirschbaum, A., & et al. (2008). Sublobar resections in stage IA non-small cell lung cancer: Segmentectomies result in significantly better cancer-related survival than wedge resections. European Journal of Cardio-Thoracic Surgery, 33(4), 728–734.
125. Sihoe, A. D. L. (2012). The evolution of VATS lobectomy. InTechOpen. https://cdn.intechopen.com/pdfs/28640.pdf
126. Sihoe, A. D. (2014). The evolution of minimally invasive thoracic surgery: Implications for the practice of uniportal thoracoscopic surgery. Journal of Thoracic Disease, 6(Suppl 6), S604–S617.
127. Sihoe, A. D., Au, S. S., Cheung, M. L., & et al. (2004). Incidence of chest wall paresthesia after video-assisted thoracic surgery for primary spontaneous pneumothorax. European Journal of Cardio-Thoracic Surgery, 25(6), 1054–1058.
128. Sihoe, A. D. L., Gonzalez-Rivas, D., Yang, T. Y., & et al. (2018). High-volume intensive training course: A new paradigm for video-assisted thoracoscopic surgery education. Interactive CardioVascular and Thoracic Surgery, 27(3), 365–371.
129. Silvestri, G. A., Gonzalez, A. V., Jantz, M. A., & et al. (2013). Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e211S–e250S.
130. Simunovic, M., Gagliardi, A., McCready, D., & et al. (2001). A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario. CMAJ, 165(4), 421–425.
131. Solomon, B. J., Ahn, J. S., Dziadziuszko, R., & et al. (2023). LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). Annals of Oncology, 34(Suppl 2), S1295–S1296.
132. Song, J. W., Oh, Y. M., Shim, T. S., & et al. (2009). Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer, 65(3), 333–338.
133. Sorin, M., Prosty, C., Ghaleb, L., & et al. (2024). Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review and meta-analysis. JAMA Oncology, 10(5), 621–633.
134. Spicer, J. D., Cascone, T., Wynes, M. W., & et al. (2024). Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: Consensus recommendations from the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 19(9), 1373–1414.
135. Spicer, J. D., Garassino, M. C., Wakelee, H., & et al. (2024). Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 404(10459), 1240–1252.
136. Stamatis, G., Djuric, D., Eberhardt, W., & et al. (2002). Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: An analysis of 350 operated patients. European Journal of Cardio-Thoracic Surgery, 22(2), 292–297.
137. Takahashi, N., Suzuki, K., Takamochi, K., & et al. (2011). Prognosis of surgically resected lung cancer with extremely high preoperative serum carcinoembryonic antigen level. General Thoracic and Cardiovascular Surgery, 59(10), 699–704.
138. Tan, D. S., Mok, T. S., & Rebbeck, T. R. (2016). Cancer genomics: Diversity and disparity across ethnicity and geography. Journal of Clinical Oncology, 34(1), 91–101.
139. Thomas, D. C. (2014). Invited commentary: Is it time to retire the "pack-years" variable? Maybe not! American Journal of Epidemiology, 179(3), 299–302.
140. Thun, M. J., Hannan, L. M., Adams-Campbell, L. L., & et al. (2008). Lung cancer occurrence in never-smokers: An analysis of 13 cohorts and 22 cancer registry studies. PLoS Medicine, 5(9), Article e185.
141. Tsai, C. H., Kung, P. T., Kuo, W. Y., & et al. (2020). Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: A national cohort study in Taiwan. BMJ Open, 10(3), Article e034351.
142. Tsuboi, M., Herbst, R. S., John, T., & et al. (2023). Overall survival with osimertinib in resected EGFR-mutated NSCLC. New England Journal of Medicine, 389(2), 137–147.
143. Van Schil, P., Van Meerbeeck, J., Kramer, G., & et al. (2005). Morbidity and mortality in the surgery arm of EORTC 08941 trial. European Respiratory Journal, 26(2), 192–197.
144. Wakelee, H., Liberman, M., Kato, T., & et al. (2023). Perioperative pembrolizumab for early-stage non-small-cell lung cancer. New England Journal of Medicine, 389(6), 491–503.
145. Wang, Y. X., Gong, J. S., Suzuki, K., & et al. (2014). Evidence based imaging strategies for solitary pulmonary nodule. Journal of Thoracic Disease, 6(7), 872–887.
146. Wolf, A. M. D., Oeffinger, K. C., Shih, T. Y., & et al. (2024). Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians, 74(1), 50–81.
147. Wu, Y. L., Dziadziuszko, R., Ahn, J. S., & et al. (2024). Alectinib in resected ALK-positive non-small-cell lung cancer. New England Journal of Medicine, 390(14), 1265–1276.
148. Wu, Y. L., Tsuboi, M., He, J., & et al. (2020). Osimertinib in resected EGFR-mutated non-small-cell lung cancer. New England Journal of Medicine, 383(18), 1711–1723.
149. Wu, L. L., Jiang, W. M., Qian, J. Y., & et al. (2023). High-risk characteristics of pathological stage I lung adenocarcinoma after resection: Patients for whom adjuvant chemotherapy should be performed. Heliyon, 9(12), Article e23207.
150. Yang, C. Y., Lin, Y. T., Lin, L. J., & et al. (2023). Stage shift improves lung cancer survival: Real-world evidence. Journal of Thoracic Oncology, 18(1), 47–56.
151. Yeh, Y. C., Kadota, K., Nitadori, J., & et al. (2016). International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. European Journal of Cardio-Thoracic Surgery, 49(1), e9–e15.
152. Yendamuri, S., Sharma, R., Demmy, M., & et al. (2013). Temporal trends in outcomes following sublobar and lobar resections for small (≤ 2 cm) non-small cell lung cancers—a Surveillance Epidemiology End Results database analysis. Journal of Surgical Research, 183(1), 27–32.
153. Zaatar, M., Stork, T., Valdivia, D., & et al. (2020). Minimal-invasive approach reduces cardiopulmonary complications in elderly after lung cancer surgery. Journal of Thoracic Disease, 12(5), 2372–2379.
154. Zhong, W. Z., Wang, Q., Mao, W. M., & et al. (2018). Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): A randomised, open-label, phase 3 study. The Lancet Oncology, 19(1), 139–148.